US Patent Issued to GlaxoSmithKline Intellectual Property Management on May 13 for "High concentration anti-blys pharmaceutical formulations" (Maryland, Kansas Inventors)

ALEXANDRIA, Va., June 12 -- United States Patent no. 12,296,007, issued on May 13, was assigned to GlaxoSmithKline Intellectual Property Management Ltd. (Stevenage, Great Britain).

"High concentration anti-blys pharmaceutical formulations" was invented by Angela Blake-Haskins (Gaithersburg, Md.), Tristan Marshall (Gaithersburg, Md.), Melissa D. Perkins (McPherson, Kan.) and Kristin O'Berry (Gaithersburg, Md.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to pharmaceutical formulations of a pharmaceutically active antigen binding protein, for example a monoclonal antibody. Such formulations comprise, in addition to the antigen binding protein, a buffering agent and a tonicity age...